ASGN
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
10/06/2026
Voltar para busca
Dado oficial do USPTO
HEPNET
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Snapshot rápido
HEPNET
ST13
US500000097855612Classe
5, 9, 40, 42
Pedido
97855612
Registro
7575493
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
31
Atualização mais recente
11/06/2026
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
5, 9, 40, 42
Data de depósito
24/03/2023
Data de registro
26/11/2024
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
26/11/2024
Última transação
11/06/2026
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Fundamento do pedido
Intent to use, Foreign priority
Código do desenho
4
Tipo de titular
84
Localização do titular
LONDON, GB
Examinador
WOOD, CAROLINE
Unidade examinadora
M10
Localização atual
FILE REPOSITORY (FRANCONIA)
Titulares e representantes
Titulares
TANGRAM THERAPEUTICS PLC
E-Therapeutics Plc
Representantes
Anna King BANNER & WITCOFF, LTD.
Classificação técnica
Classes Nice
Classe 5Classe 9Classe 40Classe 42
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
Pharmaceutical and medical preparations for use in targeting genes and silencing or inhibiting gene expression; drug delivery agents that facilitate the delivery of pharmaceutical preparations targeting genes and silencing or inhibiting gene expression; drug delivery agents that facilitate the delivery of RNAI-based and short interfering RNA-based (siRNA) medicines and pharmaceuticalsnucleic acid-based drugs (NABDs); drug delivery agents that facilitate the delivery of RNAI-based and short interfering RNA-based (siRNA) medicines and pharmaceuticalsnucleic acid-based drugs (NABDs)all for targeting genes and silencing or inhibiting gene expression; RNAi-based medicines and pharmaceuticals for use in targeting genes and blockingsilencinginhibiting gene expressionfor use in targeting mRNA and triggering its degradation; short interfering RNA-based (siRNA) medicines and pharmaceuticals for use in targeting genes and blockingsilencinginhibiting gene expressionfor use in targeting mRNA and triggering its degradation; nucleic acid-based drugs (NABDs) for use in targeting genes and blockingsilencinginhibiting gene expressionfor use in targeting mRNA and triggering its degradation; pharmaceutical and medical preparations for use in targeting messenger RNA (mRNA) and triggering its degradation
Classe 9
Downloadable and recorded computer software for use in the field of pharmaceuticalsmedicines and drug discoveryfor evaluatinganalysinginterpreting information contained in databases to identify new biological targets and gene-disease associations; downloadable and recorded artificial intelligence and machine learning software for use in the field of pharmaceuticalsmedicines and drug discoveryfor evaluatinganalysinginterpreting information contained in databases to identify new biological targets and gene-disease associations; electronic databases for use in the field of pharmaceuticalsmedicines and drug discoverydatabases containing information relating to potential biological drug targets and gene-disease associations recorded on computer media; downloadable and recorded computer platform software for use in the field of pharmaceuticalsmedicines and drug discoveryfor evaluatinganalysinginterpreting information contained in databases to identify new biological targets and gene-disease associations; downloadable and recorded computer software platforms for use in the field of pharmaceuticalsmedicines and drug discoveryfor evaluatinganalysinginterpreting information contained in databases to identify new biological targets and gene-disease associations; downloadable and recorded computer software enabling the searching and retrieval of data relating to pharmaceuticalsmedicines and drug discovery; downloadable and recorded software for the analysis of data relating to pharmaceuticalsmedicines and drug discovery; downloadable and recorded search engine software for use in the field of pharmaceuticalsmedicines and drug discovery; downloadable and recorded search engine software for the searchingretrievalindexing and analysis of data relating to pharmaceuticalsmedicines and drug discovery
Classe 40
Custom manufacture of pharmaceutical and medical preparations for use in targeting genes and blockingsilencing or inhibiting gene expression; custom manufacture of RNAi-based pharmaceuticals and medicines; custom manufacture of short interfering RNA (siRNA) medicines; custom manufacture of nucleic acid-based drugs (NABDs) for blockingsilencing or inhibiting gene expression; custom manufacture of pharmaceutical and medical preparations for use in targeting messenger RNA (mRNA) and triggering its degradation; provision of informationadvice and consultancy services relating to all of the aforesaid
Classe 42
Scientific research and development in the field of targeting genes and blockingsilencing or inhibiting gene expression; scientificpharmaceutical and medical research and development services relating to RNAi-based pharmaceuticals and medicines; scientificpharmaceutical and medical research and development services relating to pharmaceutical and medical preparations for use in targeting genes and blockingsilencing or inhibiting gene expression; scientificpharmaceutical and medical research and development services relating to short interfering RNA (siRNA) medicinesnucleic acid-based drugs (NABDs) for blocking gene expressionnucleic acid-based drugs (NABDs) for blockingsilencing or inhibiting gene expressionandpharmaceutical and medical preparations for use in targeting mRNA and triggering its degradation; drug discovery services relating to RNAi-based pharmaceuticals and medicines; drug discovery services relating to pharmaceutical and medical preparations for use in targeting genes and blockingsilencing or inhibiting gene expression; drug discovery services relating to short interfering RNA (siRNA) medicinesnucleic acid-based drugs (NABDs) for blockingsilencing or inhibiting gene expressionpharmaceutical and medical preparations for use in targeting mRNA and triggering its degradation; scientific and technical testing and data analysis in relation to pharmaceuticals and medicines; scientific and technical testing and data analysis in relation to RNAi-based medicines; scientific and technical testing and data analysis in relation to pharmaceutical and medical preparations for use in targeting genes and blockingsilencing or inhibiting gene expression; scientific and technical testing and data analysis in relation to short interfering RNA (siRNA) medicinesnucleic acid-based drugs (NABDs) for blockingsilencing or inhibiting gene expressionpharmaceutical and medical preparations for use in targeting mRNA and triggering its degradation; designdevelopmentcreation and maintenance of computer platforms and computer software for use in the field of pharmaceuticalsmedicines and drug discovery; designdevelopmentcreation and maintenance of computer platforms and computer software enabling the searching and retrieval of data relating to pharmaceuticalsmedicines and drug discovery; designdevelopmentcreation and maintenance of computer platforms and computer software for the analysis of data relating to pharmaceuticalsmedicines and drug discovery; design of and providing temporary use of online non-downloadable search engine software for use in the field of pharmaceuticalsmedicines and drug discovery; design of and providing temporary use of online non-downloadable search engine software for the searchingretrievalindexing and analysis of data relating to pharmaceuticalsmedicines and drug discovery; Platform as a Service (PaaS) services featuring computer software platforms using artificial intelligence and machine learning software and databases for use in the field of pharmaceuticalsmedicines and drug discoveryfor modelling genetic sequences and gene-disease associationsfor identifying and ranking potential gene targetsfor generating pharmaceutical and medical preparations; Platform as a Service (PaaS) services featuring computer software platforms using artificial intelligence and machine learning software and databases for use in the field of pharmaceuticalsmedicinesdrug discoveryfor generating RNAi-based medicines and pharmaceuticalsshort interfering RNA (siRNA) medicinesnucleic acid-based drugs (NABDs) for blockingsilencing or inhibiting gene expressionpharmaceutical and medical preparations for use in targeting mRNA and triggering its degradation; design and development of computer-simulated models for use in the field of pharmaceuticalsmedicines and drug discovery; providing temporary use of online non-downloadable computer software for use in the field of pharmaceuticalsmedicines and drug discoveryfor evaluatinganalysinginterpreting information contained in databases to identify new biological targets and gene-disease associations; Software as a Service (SaaS) services featuring software using artificial intelligence and machine learning software and databases in the field of pharmaceuticalsmedicines and drug discoveryfor evaluatinganalysinginterpreting information contained in databases to identify new biological targets and gene-disease associations; Software as a Service (SaaS) services featuring computer software platforms using artificial intelligence and machine learning for use in the field of pharmaceuticalsmedicines and drug discoveryfor modelling genetic sequences and gene-disease associationsfor identifying and ranking potential gene targetsfor generating RNAi-based medicines and pharmaceuticalsnucleic acid-based drugs (NABDs) for blockingsilencing or inhibiting gene expressionpharmaceutical and medical preparations for use in targeting mRNA and triggering its degradation; provision of informationadvice and consultancy services relating to all of the aforesaid
Publicações
Histórico de despachos e eventos da marca no USPTO.
31 publicações encontradas
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
26/11/2024
R.PR
REGISTERED-PRINCIPAL REGISTER
26/11/2024
DP1B
1(B) BASIS DELETED; PROCEED TO REGISTRATION
05/11/2024
IUCN
NOTICE OF ALLOWANCE CANCELLED
04/11/2024
D1BR
TEAS DELETE 1(B) BASIS RECEIVED
04/11/2024
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
07/05/2024
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
12/03/2024
PUBO
PUBLISHED FOR OPPOSITION
12/03/2024
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
21/02/2024
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
21/02/2024
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
02/02/2024
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
30/01/2024
GNEA
EXAMINERS AMENDMENT E-MAILED
30/01/2024
CNEA
EXAMINERS AMENDMENT -WRITTEN
30/01/2024
GPRN
NOTIFICATION OF PRIORITY ACTION E-MAILED
30/01/2024
GPRA
PRIORITY ACTION E-MAILED
30/01/2024
CPRA
PRIORITY ACTION WRITTEN
30/01/2024
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
26/12/2023
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
26/12/2023
ALIE
ASSIGNED TO LIE
26/12/2023
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
31/07/2023
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
18/05/2023
GNRT
NON-FINAL ACTION E-MAILED
18/05/2023
CNRT
NON-FINAL ACTION WRITTEN
18/05/2023
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
27/04/2023
GNRT
NON-FINAL ACTION E-MAILED
27/04/2023
CNRT
NON-FINAL ACTION WRITTEN
27/04/2023
DOCK
ASSIGNED TO EXAMINER
25/04/2023
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
16/04/2023
NWAP
NEW APPLICATION ENTERED
28/03/2023
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace HEPNET ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.